Financial Survey: Atossa Genetics (NASDAQ:ATOS) vs. SiBone (NASDAQ:SIBN)

Atossa Genetics (NASDAQ:ATOS) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for Atossa Genetics and SiBone, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	1	0	2	1	2.75
SiBone	1	0	3	0	2.50

Atossa Genetics presently has a consensus price target of $6.25, indicating a potential upside of 506.80%. SiBone has a consensus price target of $23.67, indicating a potential upside of 55.09%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than SiBone.

Profitability

This table compares Atossa Genetics and SiBone’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-40.28%	-37.10%
SiBone	-12.83%	-14.20%	-10.38%

Insider & Institutional Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 8.7% of Atossa Genetics shares are owned by insiders. Comparatively, 3.9% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Atossa Genetics and SiBone”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$25.50 million	($0.23)	-4.48
SiBone	$167.18 million	3.94	-$30.91 million	($0.56)	-27.25

Atossa Genetics has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Atossa Genetics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Summary

Atossa Genetics beats SiBone on 9 of the 14 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.